KyungDong Pharm home
Prescription Medicines

KD Peramivir Inj

Product Category
antiviral drugs
Active Ingredients
peramivir hydrate
Appearance
An injection filled with a colorless and transparent liquid in a colorless and transparent plastic container for intravenous fluids.
Reimbursement Code
-
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : Of 1 bag (60mL)
- Active ingredient: Peramivir hydrate (in-house specification) --- 349.4mg (300mg as peramivir)
- Additives: Sodium chloride, water for injection

2. Effectiveness
Treatment of type A or B influenza virus infection in adults and children over 2 years of age
(Administration should be started within 48 hours of the onset of initial symptoms of influenza infection.)

3. Dosage and dosage
It is advisable to start administration of this drug as soon as possible after symptom onset.
This drug is a premixed product, 1 bag (300mg/60mL) at a time. It is used only when the dosage can be replaced among adults, children over 2 years of age, and patients with renal dysfunction. Do not divide or dilute it.
1. Adult
As peramivir, 300 mg is administered as a single intravenous drip over 15 minutes.
For patients who are at risk of becoming more severe due to complications, 600 mg can be administered as a single intravenous drip over 15 minutes.
2. Children over 2 years old
As peramivir, 10 mg/kg is administered as a single intravenous drip over 15 minutes. The maximum single dose is 600 mg.
3. Patients with renal dysfunction
In adult patients with renal dysfunction, there is concern that high blood levels may persist, so the dosage is adjusted based on the table below according to the degree of decline in renal function.
*Table: Refer to attached document
There are no data on dosage adjustments of this drug in pediatric patients with renal dysfunction.
○ Intravenous drip solution administration method
It should not be used in combination with other drugs.
Discard any unused injection solution.

4. Precautions for use
1. Warning
1) When administering this drug, the necessity of this drug must be carefully reviewed.
- Regarding the administration of this drug, since administration of antiviral agents is not essential for all patients with type A or B influenza virus infection, sufficiently observe the patient's condition and carefully review the need for administration of this drug.
- Since this drug is a preparation for intravenous drip administration, carefully consider the use of other anti-influenza virus drugs such as oral or inhaled drugs, and then review the necessity of administering this drug.
- Pay attention to the drug resistance information of prevalent viruses and review the appropriateness of administering this drug.
- This drug is not effective for infections other than type A or B influenza virus infection.
- This medicine is not effective against bacterial infections.
2) The effectiveness and safety of this drug for preventive administration have not been established.
3) Among influenza patients treated with neuraminidase inhibitors, including this drug, neuropsychiatric adverse reactions such as convulsions, seizures, delirium, hallucinations, and abnormal behavior were reported, mainly in children and adolescents. In rare cases, these adverse reactions led to accidents such as falls. Severe abnormal behavior was reported more frequently in school-age children and adolescents and within 2 days of developing a fever. The effect of this drug on these adverse reactions has not been established. Neuropsychiatric adverse reactions have been reported in patients infected with influenza virus regardless of the type or use of influenza virus treatment.
Children and adolescents should be closely monitored for abnormal behavior. In addition, in order to prevent accidents such as falls due to abnormal behavior, patients and their families should be explained that there is a risk of abnormal behavior occurring after treatment with this drug and that children and adolescents should be taken into consideration so that they are not left alone for at least 2 days when receiving treatment at home.
In addition, there are reports that the same symptoms appear in cases of influenza encephalopathy, etc., so the explanation should be the same as above.

2. Do not administer to the following patients
Patients with a past history of hypersensitivity to the ingredients of this drug

3. Administer with caution to the following patients:
1) Patients with renal dysfunction (dose adjustment is required when administering this drug)
2) Elderly people (very little experience using it)
3) Additives (sodium chloride, precautions regarding water for injection)
- Patients with heart and circulatory dysfunction (there is concern that symptoms may worsen due to increased sodium load and circulating blood volume, putting a strain on the heart).
-Patients with kidney dysfunction (excessive intake of water and sodium chloride is likely to occur, and there is concern that symptoms may worsen)

4. Adverse reactions
Among 968 cases subject to safety evaluation in clinical trials targeting adults, adverse drug reactions, including abnormal changes in clinical test values, were confirmed in 239 cases (24.7%). The main symptoms were diarrhea in 56 cases (5.8%), neutrophil reduction in 27 cases (2.8%), and proteinuria in 24 cases (2.5%). In clinical trials targeting children, out of 117 cases subject to safety evaluation, adverse drug reactions, including abnormal changes in clinical test values, were confirmed in 34 cases (29.1%). The main symptoms were diarrhea in 12 cases (10.3%), neutropenia in 11 cases (9.4%), and vomiting in 6 cases (5.1%).
1) Serious adverse reactions
Decreased white blood cells, decreased neutrophils (less than 1-5%): Decreased white blood cells and neutrophils may occur, so conduct sufficient observation and take appropriate measures, such as discontinuing administration if abnormalities are found.
2) Serious adverse reactions (similar products)
Since the following serious adverse drug reactions have been reported with other anti-influenza virus preparations, sufficient observation should be conducted and appropriate measures, such as discontinuation of administration if abnormalities are confirmed, should be taken.
(1) Shock and anaphylaxis symptoms
(2) pneumonia
(3) Severe hepatitis, liver dysfunction, jaundice
(4) Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell syndrome)
(5) Acute renal failure
(6) Decrease in platelets
(7) Mental and neurological symptoms (disordered consciousness, abnormal behavior, delirium, hallucinations, delusions, convulsions, etc.)
(8) Hemorrhagic colitis
3) Other adverse reactions
* Table: Refer to attached document
4) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,024 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 1.16% (35/3,024 people, 42 cases in total) regardless of causal relationship. The occurrence rate of serious adverse events was 0.33% (10/3,024 people, 10 cases), with fever and pneumonia at 0.10% (3/3,024 people, 3 cases) each, liver function test abnormalities, sensory loss, musculoskeletal chest pain, and pulmonary embolism at 0.03% (1/3,024 people, 1 case) each. Among these, a causal relationship with this drug cannot be ruled out. The occurrence rate of serious adverse drug reactions was 0.07% (2/3,024 people, 2 cases), with liver function test abnormalities and pneumonia each reported at 0.03% (1/3,024 people, 1 case).
The occurrence rate of unexpected adverse events was 0.69% (21/3,024 people, 26 cases), including fever 0.17% (5/3,024 people, 5 cases), pneumonia 0.10% (3/3,024 people, 3 cases), constipation and runny nose each at 0.07% (2/3,024 people, 2 cases), itching, loss of sensation, Hemoptysis, hypertension, stomatitis, musculoskeletal chest pain, herpes simplex, tachycardia, indigestion, cellulitis, hypocalcemia, hypotension, pulmonary embolism, and rhabdomyolysis were reported at 0.03% each (1/3,024 people, 1 case). Among these, pneumonia was reported in 0.03% (1/3,024 people, 1 case) as an unexpected adverse drug reaction for which a causal relationship with this drug could not be ruled out.

5. General precautions
1) No treatment information has been provided for patients who are at risk or in a very bad condition requiring hospitalization. There is limited data on this drug in patients with uncontrolled diabetes, chronic respiratory disease on medication, and patients taking drugs that suppress immune function (adrenocorticosteroids, immunosuppressants). Additionally, the safety and effectiveness of this drug for repeated administration have not been established.
2) There is no data proving effectiveness for patients who started treatment 48 hours after the onset of symptoms.
3) This drug is excreted by the kidneys, and if renal function is reduced, there is a risk of continued high plasma concentration. Therefore, when administering this drug, it must be administered carefully while observing the condition according to the dosage appropriate for the creatinine clearance level.
4) Bacterial infection may appear as a complication of influenza virus infection or may be confused with influenza symptoms. If bacterial infection or bacterial infection is suspected, appropriate measures, such as administering antibacterial agents, should be taken.

6. Interaction
1) Studies have not been conducted on drug interactions with other drugs.
2) This drug is primarily excreted by the kidneys. Coadministration with drugs that decrease renal function or compete for active tubular secretion may increase plasma concentrations of this drug and may also increase the concentrations of other renally excreted drugs. When using other drugs that are excreted by the kidneys, use with caution and appropriately monitor the patient's renal function.
3) Influenza vaccine: Inactivated influenza vaccine can be administered at any time while using this medicine. However, in the case of live attenuated influenza vaccine (LAIV), antiviral drugs may reduce the effectiveness of the vaccine by inhibiting viral replication. The combination of this drug with intranasal administration of attenuated influenza vaccine has not been evaluated. Due to potential interference between these two drugs, avoid using live attenuated influenza vaccine within 2 weeks before or 48 hours after administration of this drug, unless medically advised.

7. Administration to pregnant and lactating women
1) Appropriate studies regarding the use of this drug in pregnant women have not been conducted. When administering to pregnant women or women who may be pregnant, it should be administered only when the therapeutic benefit is judged to outweigh the potential risks to the mother and fetus. No teratogenicity was observed in reproductive and developmental toxicity tests using rats and rabbits, and increased transplacental transfection in rats and increased miscarriages and premature births were reported in rabbits.
2) When administering to a nursing mother, breastfeeding should be avoided. Transition into milk has been reported in rats.

8. Administration to children
Safety and efficacy in children under 2 years of age have not been established.

9. Administration to elderly people
Clinical data on elderly people are limited, and in general, elderly people often have reduced physiological functions (renal function, liver function, etc.), so patients should be carefully observed when administering this drug.

10. Treatment in case of overdose
1) No information is available regarding overdose of this drug.
2) There is no specific antidote for overdose of this drug, and it has been reported that this drug is quickly removed from the blood by hemodialysis.

11. Application precautions
1) This drug should be used only as an intravenous drip.
2) Since this drug has not been tested for combination changes, avoid mixing it with other intravenous drugs or injecting it simultaneously into the same intravenous line.

12. Others
1) This drug has been clinically tested in Japan on 37 patients with high-risk factors (uncontrolled diabetes, chronic respiratory disease under drug treatment, taking drugs that suppress immune function (adrenocorticosteroids, immunosuppressants)).
Duration of influenza illness by administration period by administration group
* Table: Refer to attached document

5. How to save
Sealed container, stored at room temperature (1~30℃)

6. Packaging unit
60mL/Bag

7. Period of use
36 months from date of manufacture